Five-year breast cancer survivors see little relapse
NEW YORK A study released Tuesday has found that women diagnosed with breast cancer who survive five years have decreased risk of relapse.
The study, published online in the Journal of the National Cancer Institute, also found that 89 percent of patients don’t relapse 10 years after diagnosis, and 81 percent don’t relapse after 15 years.
Led by assistant professor Abenaa Brewster at the M.D. Anderson Cancer Center in Houston, the study looked at 2,838 patients who had received surgery to remove tumors and had taken cancer medication.
ActivePHR wins CDHC award
NEW YORK ActivePHR, ActiveHealth Management’s personal health record has been named a winner of the 2008 Consumer Driven Health Care Solutions Award for Most Effective Solution Provider, as awarded by CDHC Solutions magazine.
The ActivePHR program provides an electronic home for a person’s health information. ActivePHR generates actionable alerts when opportunities to improve care are identified. Other innovative features within ActivePHR include integration with ActiveHealth’s health risk assessment and disease management program, the ability to grant access to doctors/caregivers, health trackers, calendar, and translation to Spanish.
“Consumers need and want to take an increased role in their healthcare,” said Peter Neupert, corporate vice president of Microsoft Health Solutions Group. “A personal health record like ActivePHR empowers consumers. When consumers have the ability to present a complete picture of their health and information on specific issues to all of their doctors and caregivers, the result is better care.”
Danish company finds potential weight-loss drug
NEW YORK Good results from a study of a new drug from Denmark-based NeuroSearch caused the company’s stock to increase the most in more than a month, according to Bloomberg.
Studies of the experimental drug tesofensine showed that it improved fat metabolism and lowered weight. The results caused NeuroSearch’s stock to rise by about $2.20 to $50.77, a 4.5 percent increase.
The drug company said it hoped to find a partner to fund the testing required to gain regulatory approval for the drug, which could generate $1.1 billion in sales if approved.
One dollar equaled 5 kroner, as of mid-day Tuesday.